Ritalin

Cheap, 70-year-evidenced racemic stimulant for ADHD. Cleaner than amphetamines but dominated by Focalin (d-isomer-only) within the methylphenidate class for cognitive enhancement. SKIP-FOR-NOW for Dylan: modafinil is the preferred wakefulness/focus tool at 20yo and the d-isomer-only sibling (Focalin) is the cleaner version of this exact drug. Verdict flips to STRONG-CANDIDATE only with a clinical ADHD diagnosis.

Racemic methylphenidate is a 50/50 mix of two enantiomers — d-threo-methylphenidate (the active half) and l-threo-methylphenidate (the largely-inactive half).

Primary action — competitive DAT + NET reuptake inhibition:

• Methylphenidate binds the dopamine transporter (DAT) and norepinephrine transporter (NET) in a competitive, reversible manner. It does not force monoamine release like amphetamines do (no TAAR1 agonism, no VMAT2 reverse-pumping). This is the cleanest mechanistic distinction between MPH-class and amphetamine-class stimulants.
• Result: extracellular dopamine and norepinephrine rise in the synaptic cleft because reuptake is blocked. Effect ceiling is constrained by endogenous firing (no "release on demand" amphetamine effect).
• PET imaging: oral 0.25-0.5 mg/kg methylphenidate produces ~50-70% striatal DAT occupancy (Volkow et al.) — comparable to therapeutic modafinil at 200mg, but with a sharper time-course and shorter duration.

The d/l asymmetry — what the l-isomer actually does:

• d-threo-methylphenidate is ~10× more potent than l-threo at DAT/NET inhibition. This is the mechanistic basis for Focalin (d-isomer-only) being prescribed at half the mg-dose of Ritalin for equivalent CNS effect.
• The l-isomer is rapidly hydrolyzed presystemically by carboxylesterase 1A1 (CES1A1) in the gut and liver. Oral bioavailability of l-MPH is ~5% vs ~22% for d-MPH (children's PK data), so by the time the racemate reaches systemic circulation it's already heavily skewed toward d.
• However: the l-isomer is NOT pharmacologically inert. Pre-systemic l-MPH still hits hepatic and peripheral adrenergic targets before being cleared. Some literature points to l-MPH contributing to peripheral noradrenergic effects (HR, BP, GI motility) and possibly a subtle subjective "dirty" quality at higher Ritalin doses that isn't present with Focalin. The mechanistic story isn't fully settled — most modern reviews treat l-MPH as effectively a presystemic burden without therapeutic contribution, but a minority of pharmacologists argue for non-trivial l-MPH peripheral action via residual NET/alpha-adrenergic activity.
• Practical implication: Focalin at half the mg-dose gives you the same CNS effect as Ritalin with less peripheral l-isomer load. This is the entire pharmacological argument for Focalin existing.

Metabolism:

• Methylphenidate is primarily metabolized by de-esterification to ritalinic acid (pharmacologically inactive) via CES1A1.
• 78-97% renally excreted, mostly as ritalinic acid.
• Plasma protein binding low (10-33%).
• Volume of distribution: 2.65 L/kg for d-MPH, 1.80 L/kg for l-MPH.
• Minimal CYP involvement — unlike amphetamines (CYP2D6) or modafinil (CYP3A4) — which means fewer drug-drug interactions in this domain. CES1 polymorphism is the relevant pharmacogenetic axis.

Half-life: Ritalin IR has a plasma half-life of ~2-3 hours (d-MPH); clinical effect window ~3-4 hours due to receptor pharmacodynamics outlasting plasma levels modestly. Tmax 1-2 hours after oral dose. Food delays absorption mildly but doesn't change AUC meaningfully.